Ms. GINA KOLATA is the NY times reporter and Dr. Yosi is the most QUALIFIED MD to tell her about the Jan 1997 article. She might like to hear and publish the update and status of Pharmos's Project
Best regards
david
May 3, 1998
Two Drugs Eradicate Tumors in Mice
By May 3, 1998
Two Drugs Eradicate Tumors in Mice
By GINA KOLATA
ithin a year, if all goes well, the first cancer patient will be injected with two new drugs that can eradicate any type of cancer, with no obvious
side effects and no drug resistance -- in mice.
Some cancer researchers say the drugs are the most exciting treatment that they have ever seen. But then they temper their enthusiasm with caution, noting
that the history of cancer treatments is full of high expectations followed by dashed hopes when drugs with remarkable effects in animals are tested in
people.
Still, the National Cancer Institute has made the drugs their top priority, said Dr. Richard Klausner, the director. Klausner called them "the single most
exciting thing on the horizon" for the treatment of cancer.
"I am putting nothing on higher priority than getting this into clinical trials," Klausner said. The mouse studies are "remarkable and wonderful," he said,
and "very compelling." But he pointed out that the studies were in mice and so, in humans, he said he wanted to emphasize "the if's."
The new drugs, angiostatin and endostatin, work by interfering with the blood supply tumors need. Given together, they make tumors disappear and not
return.
Dr. James Pluda, who is directing the cancer institute's planned tests of the drugs in patients, said he and others at the institute were "electrified" when they
heard the drug's discoverer deliver a lecture about the newest results. "People were almost overwhelmed," Pluda said. "The data were remarkable."
Although the discovery of the drugs, and some of their effects, have been reported over the past few years, Pluda said that "if people understood how
many steps ahead" the research was compared to what had been published, "they'd be even more in awe."
But Dr. Jerome Groopman, a cancer researcher at the Harvard Medical School, was wary. "We are all driven by hope," Groopman said. "But a sober
scientist waits for the data." And until the drugs are given to humans, he said, the crucial data simply do not exist.
So far, the drugs are the only ones ever tested that can seemingly eradicate all tumors in mice, even gigantic ones, equivalent to a two-pound growth in a
person. The best that other cancer drugs have done is slow the growth of these large tumors. Mice are the traditional test animals in cancer research.
But even the drugs' discoverer, Dr. Judah Folkman, a cancer researcher at Children's Hospital in Boston, is cautious about the drugs' promise. Until patients
take them, he said, it is dangerous to make predictions. All he knows for sure, Folkman said, is that "if you have cancer and you are a mouse, we can
take good care of you."
Other scientists are not so restrained. "Judah is going to cure cancer in two years," said Dr. James Watson, a Nobel laureate who directs the Cold Spring
Harbor Laboratory, a cancer research center on Long Island. Watson said Folkman would be remembered along with scientists like Darwin as someone
who permanently altered civilization.
The long trail to the discovery of the new drugs began more than 30 years ago when Folkman became obsessed by what many saw as a quixotic notion:
that cancers cannot grow beyond the size of a pinhead unless they have their own blood supply. If he could block a tumor's blood supply, he reasoned, the
tumor should shrink to a minuscule size.
The first major break in the efforts came a decade ago when Folkman and his collaborators found drugs that did what he envisioned. He called them
anti-angiogenesis drugs because they stopped the process of developing new blood vessels, or angiogenesis. They slow tumor growth in animals but do not
eradicate the tumors. Early results in patients indicate that the drugs may slow human cancers, too. Dozens of companies are now developing such drugs.
The results with these weaker drugs were "a proof of principle," said Dr. Bart Chernow, a professor of medicine and dean for research and technology at
the Johns Hopkins University School of Medicine. Chernow is a founder of Entremed, a company in Rockville, Md., that was formed to make and market
angiostatin and endostatin as well as some of the weaker drugs that can slow cancer growth.
But the real breakthrough -- and the two new drugs -- came from Folkman's efforts to understand a peculiar phenomenon that has been known to cancer
surgeons for 100 years: sometimes a patient will have a single tumor, with no evidence whatsoever of metastases, the satellite cancers that can pepper a
patient's body. A doctor will remove the tumor and all will seem fine. But then, a few months later, a whole series of metastases will appear, grow, and
kill the patient.
In 1989, Folkman proposed a reason for the effect, which he wrote on a large white board in a room where his laboratory group had its weekly seminars.
Is it possible, he asked, that a tumor could be making both stimulators and inhibitors of blood vessel growth? If so, the inhibitors might travel through the
bloodstream, squelching metastases. When the large tumor was removed, it would no longer be a source of inhibitors, allowing the tiny metastases to
proliferate.
Folkman tried to get one of his doctoral or post-doctoral students to work on that idea. "Each Friday, at our meeting," he said "I would say, 'Here's a great
experiment.' But no one wanted to work on it." It seemed too wild, Folkman said, too unlikely to result in findings that would end up in a scientific
journal, a major goal of young scientists.
Then, in 1991, a post-doctoral student, Michael O'Reilly, decided to take on the challenge. O'Reilly focused on a particularly deadly mouse cancer that
grows to the equivalent of a two-pound tumor in a person.
As long as mice had the large tumor, they had no signs of metastases. But five days after the tumors were surgically removed, metastases invariably sprang
up in the animals' lungs. Within 15 days, the animals would be dead, their lungs packed with large red tumors, like grapes.
Eventually, after arduous work in collaboration with chemists, O'Reilly discovered that the large tumors made a substance that stymied the growth of other
tumors. This substance showed up in the animals' urine, but was present in such minute quantities that O'Reilly had to collect 10 quarts of mouse urine to
obtain 30-thousandth of an ounce of the mysterious substance. It turned out to be a piece of a larger and very common protein, plasminogen, that the body
uses in blood clotting. Folkman named it angiostatin.
Apparently, cells can use the plasminogen gene for two purposes: they can use it at its full length to make plasminogen, or they can use just a piece of it
and make angiostatin. Plasminogen does nothing to stop tumor growth. The question was, would angiostatin?
Folkman and O'Reilly discovered that angiostatin also appears, in minute quantities, in human blood. Using outdated human blood discarded by the Red
Cross, they extracted enough angiostatin to treat mice. Then they began their experiment.
They had 20 mice with large tumors on their backs. The investigators removed the tumors and then injected half of the mice with angiostatin each day and
the others with salt water, as a comparison.
After 15 days, the researchers killed the mice and cut them open. As more than a dozen scientists gathered around a table in the laboratory, O'Reilly
opened the first mouse. It had huge tumors filling its lungs. Then Folkman checked a notebook to see what the animal had received: salt water. They
looked at the next mouse. No tumors. Folkman checked to see the treatment: angiostatin. And so it went. All 10 of the mice that had been injected with
angiostatin were free of cancer. All 10 of those that had been received salt water had huge new tumors.
The room was buzzing, the scientists were grinning. Folkman said. Everyone in the room knew what the results meant, and they were elated. They
responded, he said, like men at a football game. "Everyone clapped O'Reilly on the back," Folkman said.
Then the researchers found a second protein fragment, secreted by tumors, that also squelches metastases, Folkman said. It was a piece of a different
protein, collagen 18, that is in all blood vessels but by itself has no effect on cancer. They named the collagen fragment endostatin.
"It was even more potent than angiostatin," Folkman said. If he gave it to a mouse with a huge tumor, he said, the equivalent of one weighing a pound
and a half in a human, endostatin would shrink the cancer down to a microscopic size.
Moreover, tumors never became resistant to endostatin, said Folkman, who added that he had given the drug to mice with large tumors and they had
shrunk to almost nothing. He stopped the drug, he said, and the tumors grew back. Then he gave the drug continuously for the rest of the animals' lives.
The tumors remained small and harmless and the animals remained healthy.
Dr. Robert Kerbel, a cancer researcher at Sunnybrook Health Science Center in Toronto, said he was not surprised that the cancers never became resistant
to endostatin. Tumors become resistant to chemotherapy drugs, Kerbel said, because cancer cells constantly reshuffle their genetic information. The result, he
said, is that the tumors spin off mutant cells that resist the drugs and, ultimately, the tumors grow back, invulnerable.
But, Kerbel said, angiostatin and endostatin do not act on tumors. Instead, they act on normal blood vessels that feed tumors. And normal cells, he said, do
not reshuffle their genes and so do not develop drug resistance. That is why chemotherapy drugs continue to devastate normal cells -- causing bone marrow
suppression, loss of hair, nausea and vomiting -- even when the cancer cells have grown impervious to their effects, Kerbel said.
Then Folkman discovered that he could actually obliterate tumors in mice with his new drugs. He gave endostatin and angiostatin together, treating mice for
25 days. To his surprise, Folkman said, "there was no tumor left -- we couldn't even find it with a microscope." The tumors, he said, "were eradicated."
And the drugs seem to have no side effects, at least in mice, something that Folkman acknowledges is hard for researchers to believe. But, he said, he had
given mice up to four times the doses needed to eliminate cancer and could not find any adverse effects. These two human proteins may be, he said,
"exquisitely aimed -- we do not know why -- at cancer."
In contrast, Folkman said, mice become very ill when they receive commonly used chemotherapy -- their hair falls out, they bleed, they refuse to eat.
For the past four years, Folkman said, he and his colleagues have found that all tumors responded to the drugs in the same way. Even leukemia, a blood
tumor, responds, he said, because it turns out that leukemia needs to form new blood vessels in the bone marrow to grow. Leukemia tumors grow on these
blood vessels, "like berries on a bush," Folkman said, shedding cancer cells into the blood.
But Folkman is the first to urge caution in leaping to conclusions about what might happen when patients try the drugs. "Going from mice to people is a
big jump, with lots of failures," he said.
Hopes were high for chemotherapy drugs that worked well in mice but turned out to be less successful in people. Therapies that used the immune system
to rid the body of cancer also worked in mice but were disappointing when they were tried in people. Gene therapy treats mouse cancer, but has had
limited success in people. From bitter experience, most cancer researchers have learned to be leery of what one called "that four letter word" -- cure.
ithin a year, if all goes well, the first cancer patient will be injected with two new drugs that can eradicate any type of cancer, with no obvious
side effects and no drug resistance -- in mice.
Some cancer researchers say the drugs are the most exciting treatment that they have ever seen. But then they temper their enthusiasm with caution, noting
that the history of cancer treatments is full of high expectations followed by dashed hopes when drugs with remarkable effects in animals are tested in
people.
Still, the National Cancer Institute has made the drugs their top priority, said Dr. Richard Klausner, the director. Klausner called them "the single most
exciting thing on the horizon" for the treatment of cancer.
"I am putting nothing on higher priority than getting this into clinical trials," Klausner said. The mouse studies are "remarkable and wonderful," he said,
and "very compelling." But he pointed out that the studies were in mice and so, in humans, he said he wanted to emphasize "the if's."
The new drugs, angiostatin and endostatin, work by interfering with the blood supply tumors need. Given together, they make tumors disappear and not
return.
Dr. James Pluda, who is directing the cancer institute's planned tests of the drugs in patients, said he and others at the institute were "electrified" when they
heard the drug's discoverer deliver a lecture about the newest results. "People were almost overwhelmed," Pluda said. "The data were remarkable."
Although the discovery of the drugs, and some of their effects, have been reported over the past few years, Pluda said that "if people understood how
many steps ahead" the research was compared to what had been published, "they'd be even more in awe."
But Dr. Jerome Groopman, a cancer researcher at the Harvard Medical School, was wary. "We are all driven by hope," Groopman said. "But a sober
scientist waits for the data." And until the drugs are given to humans, he said, the crucial data simply do not exist.
So far, the drugs are the only ones ever tested that can seemingly eradicate all tumors in mice, even gigantic ones, equivalent to a two-pound growth in a
person. The best that other cancer drugs have done is slow the growth of these large tumors. Mice are the traditional test animals in cancer research.
But even the drugs' discoverer, Dr. Judah Folkman, a cancer researcher at Children's Hospital in Boston, is cautious about the drugs' promise. Until patients
take them, he said, it is dangerous to make predictions. All he knows for sure, Folkman said, is that "if you have cancer and you are a mouse, we can
take good care of you."
Other scientists are not so restrained. "Judah is going to cure cancer in two years," said Dr. James Watson, a Nobel laureate who directs the Cold Spring
Harbor Laboratory, a cancer research center on Long Island. Watson said Folkman would be remembered along with scientists like Darwin as someone
who permanently altered civilization.
The long trail to the discovery of the new drugs began more than 30 years ago when Folkman became obsessed by what many saw as a quixotic notion:
that cancers cannot grow beyond the size of a pinhead unless they have their own blood supply. If he could block a tumor's blood supply, he reasoned, the
tumor should shrink to a minuscule size.
The first major break in the efforts came a decade ago when Folkman and his collaborators found drugs that did what he envisioned. He called them
anti-angiogenesis drugs because they stopped the process of developing new blood vessels, or angiogenesis. They slow tumor growth in animals but do not
eradicate the tumors. Early results in patients indicate that the drugs may slow human cancers, too. Dozens of companies are now developing such drugs.
The results with these weaker drugs were "a proof of principle," said Dr. Bart Chernow, a professor of medicine and dean for research and technology at
the Johns Hopkins University School of Medicine. Chernow is a founder of Entremed, a company in Rockville, Md., that was formed to make and market
angiostatin and endostatin as well as some of the weaker drugs that can slow cancer growth.
But the real breakthrough -- and the two new drugs -- came from Folkman's efforts to understand a peculiar phenomenon that has been known to cancer
surgeons for 100 years: sometimes a patient will have a single tumor, with no evidence whatsoever of metastases, the satellite cancers that can pepper a
patient's body. A doctor will remove the tumor and all will seem fine. But then, a few months later, a whole series of metastases will appear, grow, and
kill the patient.
In 1989, Folkman proposed a reason for the effect, which he wrote on a large white board in a room where his laboratory group had its weekly seminars.
Is it possible, he asked, that a tumor could be making both stimulators and inhibitors of blood vessel growth? If so, the inhibitors might travel through the
bloodstream, squelching metastases. When the large tumor was removed, it would no longer be a source of inhibitors, allowing the tiny metastases to
proliferate.
Folkman tried to get one of his doctoral or post-doctoral students to work on that idea. "Each Friday, at our meeting," he said "I would say, 'Here's a great
experiment.' But no one wanted to work on it." It seemed too wild, Folkman said, too unlikely to result in findings that would end up in a scientific
journal, a major goal of young scientists.
Then, in 1991, a post-doctoral student, Michael O'Reilly, decided to take on the challenge. O'Reilly focused on a particularly deadly mouse cancer that
grows to the equivalent of a two-pound tumor in a person.
As long as mice had the large tumor, they had no signs of metastases. But five days after the tumors were surgically removed, metastases invariably sprang
up in the animals' lungs. Within 15 days, the animals would be dead, their lungs packed with large red tumors, like grapes.
Eventually, after arduous work in collaboration with chemists, O'Reilly discovered that the large tumors made a substance that stymied the growth of other
tumors. This substance showed up in the animals' urine, but was present in such minute quantities that O'Reilly had to collect 10 quarts of mouse urine to
obtain 30-thousandth of an ounce of the mysterious substance. It turned out to be a piece of a larger and very common protein, plasminogen, that the body
uses in blood clotting. Folkman named it angiostatin.
Apparently, cells can use the plasminogen gene for two purposes: they can use it at its full length to make plasminogen, or they can use just a piece of it
and make angiostatin. Plasminogen does nothing to stop tumor growth. The question was, would angiostatin?
Folkman and O'Reilly discovered that angiostatin also appears, in minute quantities, in human blood. Using outdated human blood discarded by the Red
Cross, they extracted enough angiostatin to treat mice. Then they began their experiment.
They had 20 mice with large tumors on their backs. The investigators removed the tumors and then injected half of the mice with angiostatin each day and
the others with salt water, as a comparison.
After 15 days, the researchers killed the mice and cut them open. As more than a dozen scientists gathered around a table in the laboratory, O'Reilly
opened the first mouse. It had huge tumors filling its lungs. Then Folkman checked a notebook to see what the animal had received: salt water. They
looked at the next mouse. No tumors. Folkman checked to see the treatment: angiostatin. And so it went. All 10 of the mice that had been injected with
angiostatin were free of cancer. All 10 of those that had been received salt water had huge new tumors.
The room was buzzing, the scientists were grinning. Folkman said. Everyone in the room knew what the results meant, and they were elated. They
responded, he said, like men at a football game. "Everyone clapped O'Reilly on the back," Folkman said.
Then the researchers found a second protein fragment, secreted by tumors, that also squelches metastases, Folkman said. It was a piece of a different
protein, collagen 18, that is in all blood vessels but by itself has no effect on cancer. They named the collagen fragment endostatin.
"It was even more potent than angiostatin," Folkman said. If he gave it to a mouse with a huge tumor, he said, the equivalent of one weighing a pound
and a half in a human, endostatin would shrink the cancer down to a microscopic size.
Moreover, tumors never became resistant to endostatin, said Folkman, who added that he had given the drug to mice with large tumors and they had
shrunk to almost nothing. He stopped the drug, he said, and the tumors grew back. Then he gave the drug continuously for the rest of the animals' lives.
The tumors remained small and harmless and the animals remained healthy.
Dr. Robert Kerbel, a cancer researcher at Sunnybrook Health Science Center in Toronto, said he was not surprised that the cancers never became resistant
to endostatin. Tumors become resistant to chemotherapy drugs, Kerbel said, because cancer cells constantly reshuffle their genetic information. The result, he
said, is that the tumors spin off mutant cells that resist the drugs and, ultimately, the tumors grow back, invulnerable.
But, Kerbel said, angiostatin and endostatin do not act on tumors. Instead, they act on normal blood vessels that feed tumors. And normal cells, he said, do
not reshuffle their genes and so do not develop drug resistance. That is why chemotherapy drugs continue to devastate normal cells -- causing bone marrow
suppression, loss of hair, nausea and vomiting -- even when the cancer cells have grown impervious to their effects, Kerbel said.
Then Folkman discovered that he could actually obliterate tumors in mice with his new drugs. He gave endostatin and angiostatin together, treating mice for
25 days. To his surprise, Folkman said, "there was no tumor left -- we couldn't even find it with a microscope." The tumors, he said, "were eradicated."
And the drugs seem to have no side effects, at least in mice, something that Folkman acknowledges is hard for researchers to believe. But, he said, he had
given mice up to four times the doses needed to eliminate cancer and could not find any adverse effects. These two human proteins may be, he said,
"exquisitely aimed -- we do not know why -- at cancer."
In contrast, Folkman said, mice become very ill when they receive commonly used chemotherapy -- their hair falls out, they bleed, they refuse to eat.
For the past four years, Folkman said, he and his colleagues have found that all tumors responded to the drugs in the same way. Even leukemia, a blood
tumor, responds, he said, because it turns out that leukemia needs to form new blood vessels in the bone marrow to grow. Leukemia tumors grow on these
blood vessels, "like berries on a bush," Folkman said, shedding cancer cells into the blood.
But Folkman is the first to urge caution in leaping to conclusions about what might happen when patients try the drugs. "Going from mice to people is a
big jump, with lots of failures," he said.
Hopes were high for chemotherapy drugs that worked well in mice but turned out to be less successful in people. Therapies that used the immune system
to rid the body of cancer also worked in mice but were disappointing when they were tried in people. Gene therapy treats mouse cancer, but has had
limited success in people. From bitter experience, most cancer researchers have learned to be leery of what one called "that four letter word" -- cure. |
